ERBB2 and breast cancer: Another retrospective study that included 1,973 Austrian patients showed that individuals struggling with HR+/HER2-low and HR-/HER2-low metastatic BC had higher 5-year OS (11% and 33%, respectively) and 5-year PFS (37% and 6%, respectively) (Gampenrieder et al., 2021).